PerkinElmer Opens New Diagnostics Facility in Chennai
Laboratory Expands Access to Innovative Solutions for Safer
Pregnancies and Healthier Babies in India
WALTHAM, Mass. & CHENNAI, India–(BUSINESS WIRE)–PerkinElmer,
Inc., a global leader focused on improving the health and safety of
people and the environment, has expanded its footprint in India with the
opening of a new diagnostics facility in Chennai, Tamil Nadu. The
laboratory will provide a comprehensive menu of diagnostic screening
services to hospitals, maternity nursing facilities, diagnostic labs and
clinicians throughout India.
Prahlad Singh, President, Diagnostics, PerkinElmer formally inaugurated
the facility today in the presence of a leading group of clinicians,
including gynecologists, fetal medicine specialists and pediatricians,
along with medical research professionals and key opinion leaders.
Since 1981, PerkinElmer has been providing instruments and services to
customers in India, spanning a wide range of markets. The opening of the
Chennai laboratory broadens PerkinElmer’s diagnostic offerings to
respond to India’s growing need for easier access to technologies that
can screen for and help diagnose prenatal and neonatal conditions.
Newborn screening helps detect metabolic and other inherited disorders
that are treatable only when identified during the first few days of
life.
“We are experiencing a steady rise in demand for maternal fetal health
and newborn screening solutions in India as hospitals, clinicians and
expectant parents strive to ensure healthier outcomes through early
detection, diagnosis and proper management of prenatal and neonatal
conditions,” said Jayashree Thacker, President, PerkinElmer India. “This
state-of-the art laboratory underscores our commitment to our continued
expansion plans in India. By increasing our capacity to accommodate
higher testing volumes, offer a comprehensive and growing menu of
diagnostic assays, and provide a hands-on experience with our innovative
technologies, we are further supporting India’s healthcare requirements.”
The Chennai laboratory extends PerkinElmer’s capabilities in India with
a widened set of assays related to cytogenetics and molecular
diagnostics. PerkinElmer will also provide customer service and support,
along with product training and demonstrations, at the Chennai
laboratory. A newborn screening application facility within the lab will
showcase PerkinElmer’s programs and includes visual aids, equipment
platforms and application software to support key stakeholders.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The Company reported revenue of
approximately $2.3 billion in 2015, has approximately 8,000 employees
serving customers in more than 150 countries, and is a component of the
S&P 500 Index.
The Company established direct operations in India in 2004 and currently
has more than 6,000 customers there across several markets including
diagnostics, pharmaceuticals, biotech, food, agriculture, chemicals,
plastics, automobile and academic research labs.
PerkinElmer’s global diagnostic offerings include: prenatal, neonatal
and infectious disease screening, along with molecular diagnostics
solutions, through its wide range of instruments, reagents and assay
platforms, and software. The Company also provides private cord blood
and cord tissue preservation to families through ViaCord, LLC.
Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements relating to estimates and
projections of future earnings per share, cash flow and revenue growth
and other financial results, developments relating to our customers and
end-markets, and plans concerning business development opportunities and
divestitures. Words such as “believes,” “intends,” “anticipates,”
“plans,” “expects,” “projects,” “forecasts,” “will” and similar
expressions, and references to guidance, are intended to identify
forward-looking statements. Such statements are based on management’s
current assumptions and expectations and no assurances can be given that
our assumptions or expectations will prove to be correct. A number of
important risk factors could cause actual results to differ materially
from the results described, implied or projected in any forward-looking
statements. These factors include, without limitation: (1) markets into
which we sell our products declining or not growing as anticipated; (2)
fluctuations in the global economic and political environments; (3) our
failure to introduce new products in a timely manner; (4) our ability to
execute acquisitions and license technologies, or to successfully
integrate acquired businesses and licensed technologies into our
existing business or to make them profitable, or successfully divest
businesses; (5) our failure to adequately protect our intellectual
property; (6) the loss of any of our licenses or licensed rights; (7)
our ability to compete effectively; (8) fluctuation in our quarterly
operating results and our ability to adjust our operations to address
unexpected changes; (9) significant disruption in third-party package
delivery and import/export services or significant increases in prices
for those services; (10) disruptions in the supply of raw materials and
supplies; (11) the manufacture and sale of products exposing us to
product liability claims; (12) our failure to maintain compliance with
applicable government regulations; (13) regulatory changes; (14) our
failure to comply with healthcare industry regulations; (15) economic,
political and other risks associated with foreign operations; (16) our
ability to retain key personnel; (17) significant disruption in our
information technology systems; (18) our ability to obtain future
financing; (19) restrictions in our credit agreements; (20) our ability
to realize the full value of our intangible assets; (21) significant
fluctuations in our stock price; (22) reduction or elimination of
dividends on our common stock; and (23) other factors which we describe
under the caption “Risk Factors” in our most recent quarterly report on
Form 10-Q and in our other filings with the Securities and Exchange
Commission. We disclaim any intention or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this press release.
Contacts
Media Contact:
PerkinElmer, Inc.
Raghu Basiboina,
+91.97.3987.7272
raghu.basiboina@perkinelmer.com
